Treatment with immune checkpoint inhibitors (ICI), e.g. targeting programmed death ligand 1 (PD-L1) or its receptor programmed cell death protein 1 (PD-1), have improved the therapy of many cancers but failed in PDAC yet. Here, PDCD1 is linked to cancer.